Development of AAV Therapeutics
Last year’s FDA approval for Spark Therapeutics’ Luxturna™ for inherited retinal disease marked the first approval for an adeno-associated virus (AAV)-based therapy in the USA. This follows approval in Europe for AAV therapeutic Glybera® (UniQure) in 2012 for the treatment of ultra-rare hereditary lipoprotein lipase deficiency, but this was subsequently withdrawn due to the lack of commercial success. Nevertheless, the marketing approvals of these therapeutics shows the increasing maturity of AAV-based therapeutics.
The regulatory success is the result of increasing research and development on AAV therapeutics. The UK has a strong presence in this area and this meeting will bring together professionals from industry and academia to disseminate and share information on the development of adeno-associated virus therapeutics, with a focus on the manufacturing process, as well as highlighting areas of need for this community.
In addition to oral presentations there will be an opportunity to present posters. Selected poster presenters will be invited to present a poster flash.
The agenda will be published soon.
There will be an opportunity through partnering software to set up 1-2-1 meetings on the day at various networking times, to maximise opportunities for interaction and future collaborations. We hope that you can make the most of this and please do engage and accept meetings where possible.
Call for Posters
There will be an opportunity for researchers to present posters. Please note your interest on registration and use the free text box to provide a descriptive title.
Please note, places for this event are limited and if the meeting is oversubscribed, places will be prioritised for those who are technical practitioners in the sector.